Company Announcements

Regulatory announcements

20.06.17 Board Change
24.05.17 Results of Annual General Meeting
18.05.17 Award of Deferred Bonus Share Options
28.04.17 Posting of 2016 Annual Report and Financial Statements
20.04.17 Audited 2016 Preliminary Results
13.04.17 Trading Update
05.04.17 Directors’ Dealings
21.02.17 hVIVO notes the initiation of a Phase I clinical trial with AGS-v
09.02.17 Data from PrEP Biopharm’s two Phase IIa clinical studies
05.01.17 Directors’ Dealings
30.12.16 Change of auditor
12.10.16 Directors’ Dealings
23.09.16 Exercise of Share Options
22.09.16 Half-year Financial Report
21.09.16 Trading update
02.09.16 hVIVO Landmark Asthma Study Underway
04.08.16 Directors’ Dealings
14.06.16 Favourable results for PrEP Biopharm’s Flu Study
24.05.16 David Norwood Lock-in Deed
23.05.16 Result of Annual General Meeting
28.04.16 Posting of 2015 Annual Report and Financial Statements
25.04.16 Initial results for PrEP Biopharm’s PrEP-001 Phase IIa Flu Study
22.04.16 Joint Venture Investment with the SEEK Group
20.04.16 Board Changes
20.04.16 Audited 2015 Preliminary Results
14.04.16 Directors’ Dealings
06.01.16 Directors’ Dealings
15.12.15 Result of General Meeting
26.11.15 Conditional Placing to raise £20.5 million
02.11.15 hVIVO invests in PrEP Biopharm Limited
02.11.15 Trading Update
05.10.15 Directors’ Dealings
24.09.15 Half Yearly Report
06.07.15 Directors’ Dealings
25.06.15 Exercise of Share Options
26.05.15 Result of AGM
14.05.15 Director’s Dealings
13.05.15 Exercise of Share Options
08.05.15 Director’s Dealings
30.04.15 Director’s Dealings
24.04.15 Posting of 2014 Annual Report and Financial Statements
21.04.15 Award of Share Options
16.04.15 Audited 2014 Preliminary Results
16.04.15 Confirmation of change of name to hVIVO plc
13.04.15 Change of Name to hVIVO
08.04.15 Directors’ Dealings
04.03.15 Issue of Ordinary Shares
16.02.15 Trading Update
09.01.15 Directors’ Dealings
25.11.14 Trading Update
06.11.14 Director’s Dealings
04.11.14 Director’s Dealings
07.10.14 Board change
25.09.14 Half Yearly Report
01.09.14 Result of General Meeting
21.08.14 hVIVO HCM of GS-5086 in RSV for Gilead Sciences
14.08.14 Conditional Placing to raise £33.6 million
28.07.14 hVIVO HCM study of AL-8176 in RSV for Alios BioPharma
14.07.14 Board change
26.06.14 Board change
12.06.14 Board changes
04.06.14 Start of hVIVO challenge study in asthma
02.06.14 Investor Event
21.05.14 Result of AGM
17.04.14 Posting of 2013 Annual Report and Accounts
09.04.14 Board Changes
09.04.14 Audited 2013 Preliminary Results
19.03.14 New state of the art biomedical facility in UK
04.03.14 Acquisition
16.12.13 Trading Update
26.09.13 Half Yearly Report
28.08.13 Contract Win
23.08.13 Contract Win
02.07.13 Result of General Meeting
01.07.13 Contract Win
14.06.13 Conditional Placing to raise £25.5 million
19.04.13 Posting of 2012 Annual Report and Accounts
10.04.13 Audited 2012 Preliminary Results
07.01.13 Contract Win
12.12.12 Trading Update
22.10.12 Contract Win
24.09.12 Half Yearly Report
10.05.12 Contract Win
03.05.12 First day of Dealings and Admission to AIM

Get in touch

Give us a call, or drop us an email. We'd love to hear from you!

Get in touch now